IN8bio (INAB) announces the appointment of Jeremy Graff, Ph.D., to its Board of Directors. With over two decades of experience in drug development and leadership within the biotechnology and pharmaceutical sectors, Dr. Graff currently serves as the Chief Scientific Officer at IMV Inc (IMV), an early-stage Canadian biotechnology company.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INAB:
- IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting
- IN8bio receives orphan drug designation for INB-400/410
- IN8bio treatment of malignant glioma granted FDA orphan status
- IN8bio Soars after Promising Drug Data
- IN8bio announces new data from Phase 1 trial of INB-100
